Breast medical oncologist and early drug development specialist @breastcancerdoc.bsky.social discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field of #breastcancer on @emjreviews.bsky.social lastest podcast. 🎙️ Listen here: bit.ly/422CWXd

Fantastic news for patients! OS benefit with adjuvant abemaciclib for 2 years for high-risk node positive patients. Congratulations to everyone involved with monarchE. Awaiting details at an upcoming meeting investor.lilly.com/news-release...

Congrats to @breastcancerdoc.bsky.social, Nicholas Turner of @bcrfcure.bsky.social, & the team on their @NEJM study of overall survival results of inavolisib for PIK3CA-mutated #breastcancer. Dr. Turner will share more at 2:07 p.m. CT at #ASCO25. @mskcancercenter.bsky.social bit.ly/43xNnn3

Session alert below with MSK expert @breastcancerdoc.bsky.social. #ASCO25

Whether you are attending @ASCO in person or virtually, join us for the educational session - “After a CDK4/6 inhibitor: State of theArt in HR+ MBC “today at 4.30 PM on Hall D2 - Seth Wander, Ricki Fairley, Rena Callahan @MSKCancerCenter @OncoAlert #bcsm #ASCO2025

In this video @breastcancerdoc.bsky.social discusses the results of the phase III EMBER-3 trial of imlunestrant. She presented on this oral selective estrogen receptor degrader for #breastcancer treatment at #SABCS24. ascopost.com/videos/2024-...

When @breastcancerdoc.bsky.social & I are unintentionally matching at our poster on T-DXd in pts with HER2-low lobular MBC. PFS 7.2m in total cohort, shorter in those with PIK3CA/AKT/PTEN muts & trend toward longer in HER2mut. More research needed in lobular BC!

Oral SERD #Imlunestrant in #EMBER3 is shifting the game! No need to check for ESR1 mutations when combined with #verzenio, as revealed by @breastcancerdoc.bsky.social at @sabcs.bsky.social Insightful discussion by @DrBurstein #BreastCancer #OncologyBreakthroughs www.nejm.org/doi/full/10....

New results from a clinical trial by MSK expert Dr. Komal Jhaveri (@breastcancerdoc.bsky.social) show an experimental drug (#imlunestrant) stops advanced #breastcancer from progressing in some people with tumors that have grown resistant to standard therapy. Learn more: bit.ly/3D3Qc4b

Congrats to Komal Jhaveri on the amazing results of her @nejm.org study that found imlunestrant–abemaciclib combo significantly improved progression-free survival for people with ER+, HER2- advanced #breastcancer. She presented this work at #SABCS24! @breastcancerdoc.bsky.social buff.ly/3OR1Ulj ➡️

Super plenary from Komal Jhaveri on imlunestrant #sabcs Congrats to her and the Ember-3 trial authors for developing this SERD (and combo with Abema)

www.nejm.org/doi/full/10.... Imlunestrant with or without abema out in @nejm.org this morning. 📍Imlunestrant alone beneficial in only ESR1 subgroup. 📍With abema, benefits all. #SABCS24 @sabcs.bsky.social @breastcancerdoc.bsky.social

EMBER3 now in @NEJM highlights imlunestrant is better than fulvestrant in mESR1 MBC, and combo of abema+ imlumnestrant is better independent of mutations in all Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al! www.nejm.org/doi/full/10....

EMBER3 Interesting subgroup breakdown shows the combo benefit persists independent of ESR1 status, prior CDK4/6 inhibition, and shows signal for CNS effect (very small numbers) #SABCS24 @breastcancerdoc.bsky.social @oncoalert.bsky.social @sabcs.bsky.social

Ember3: Safety profile of imlunestrant looks good—minimal GI toxicity, no class toxicity concerns. The combo AEs are what we expect with abema. #SABCS24 @breastcancerdoc.bsky.social @oncoalert.bsky.social

#EMBER3 results presented @sabcs.bsky.social #SABCS24 by @breastcancerdoc.bsky.social Main take aways: 1) Imlunestrant ⬆️ PFS > SOC in 1L, ESR1 mut, mER+ BC 2) Imlunestrant + abemaciclib ⬆️ PFS in 1L mER+ BC irrespective of ESR1 or PIK3CA mut 3) Imlunestrant ⬇️ CNS progression 4) OS immature #bcsm

Another up and coming (ie, may well be fda approved in the near future) agent is imlunestrant, as monotherapy or in combo with abemaciclib #SABCS24 @breastcancerdoc.bsky.social

First Bluesky post! EMBER-3 presented by my mentor @breastcancerdoc.bsky.social demonstrating greater mPFS as single agent vs. SOC ET in ESR1mut, and impressive benefit of imlunestrant+abema with mPFS 9.4 months, 59% had prior CDK4/6i. Novel ET + CDK4/6i switch is intriguing - ELAINE3 is enrolling!

What a fantastic start to #sabcs24 hoping this to be the new SABCS tradition @vkaklamani.bsky.social #firstofmanymore